Galderma R&D Evaluates Safety of Restylane Lyft for Chin Augmentation
A study is underway to assess the safety of Restylane Lyft with Lidocaine for chin augmentation after retreatment.
Asset / Drug
Drug and asset intelligence for Galderma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Topline Data
July 20, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.